Fig. 2

Plasma ONO-5334 concentrations following administration and those required for different levels of sCTX inhibition. Plasma ONO-5334 concentrations at 100 mg QD, 300 mg QD and 50 mg BID in the MAD study are shown. At 50 mg BID, plasma ONO-5334 concentrations between 12 and 24 h after administration are substituted by values between 0 and 12 h. ONO-5334 concentrations required for sCTX inhibition of 20, 50, 80 and 99% Emax are indicated. The plasma ONO-5334 concentration in the MAD study was reported by Nagase et al. [29]